Sebaceous hyperplasia: systemic treatment with isotretinoin

The study aimed to verify the therapeutic action of isotretinoin in the treatment of sebaceous hyperplasia. During two months, 20 patients with sebaceous hyperplasia took isotretinoin at a dosage of 1mg/kg per day. Their skin lesions were counted and photographed before and after treatment and re-ev...

Full description

Saved in:
Bibliographic Details
Published in:Anais brasileiros de dermatología 2015-04, Vol.90 (2), p.211-215
Main Authors: Tagliolatto, Sandra, Santos Neto, Octavio de Oliveira, Alchorne, Maurício Mota de Avelar, Enokihara, Mauro Yoshiaki
Format: Article
Language:English
Subjects:
Adult
Clinical trial
Dermatologic Agents - therapeutic use
DERMATOLOGY
Female
Humans
Hyperplasia - drug therapy
Investigation
Isotretinoin
Isotretinoin - therapeutic use
Sebaceous Gland Diseases
Sebaceous Gland Diseases - drug therapy
Sebaceous Glands - pathology
Skin - drug effects
Statistics, Nonparametric
Therapies, investigational
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aimed to verify the therapeutic action of isotretinoin in the treatment of sebaceous hyperplasia. During two months, 20 patients with sebaceous hyperplasia took isotretinoin at a dosage of 1mg/kg per day. Their skin lesions were counted and photographed before and after treatment and re-evaluated two years later. The average number of sebaceous hyperplasia lesions before treatment was 24 per patient. At the end of two months of therapy, the number of lesions decreased to 2 per patient. The statistically analyzed data showed a reduction in the number of lesions following isotretinoin use (p < 0.05). Two years after the end of the treatment, the average number of sebaceous hyperplasia lesions was 4 per patient. There were no severe side effects. Thus, the data analysis suggests that isotretinoin is a safe and effective drug for treating the disease under study.
ISSN:0365-0596
1806-4841
1806-4841
0365-0596
DOI:10.1590/abd1806-4841.20153192